MedTrace Logo

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

NCT04246359 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-04-07

No results posted yet for this study

Summary

A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.

Conditions

  • Lymphoma, B-Cell

Interventions

DRUG

Rituximab Biosimilar

To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.

DRUG

Pegylated Interferon α-2b

To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.

Sponsors & Collaborators

  • Huiqiang Huang

    lead OTHER

Principal Investigators

  • Ye Cao, Professor · Ethics Committee of Cancer Center of Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2022-06-16
Completion
2023-01-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246359 on ClinicalTrials.gov